New compound boosts treatment for aggressive breast cancer
Triple-negative breast cancer tumors can be particularly aggressive, and they tend to occur in women with a defective BRCA1 gene.
It is estimated that approximately 12 percent of breast cancers are triple-negative.
New research, which has recently been published in the journal Science Translational Medicine, tests the effect of a novel anticancer agent on treating different types of breast cancer and finds that a new compound - when administered in combination with conventional anticancer drugs - is "highly effective" for treating both triple negative and HER2 positive breast cancers.
As the authors of the new study note, treatment for triple-negative breast cancer has seen little improvement in the past 30 years, so the recent findings are particularly welcome in this context.
To read the full article, click HERE
Written by Ana Sandoiu for medicalnewstoday.com